Iterum Therapeutics Provides Business Update DUBLIN and CHICAGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a general business update. ORLYNVAHTM Launch Update In partnership with EVERSANA Life Science Services, LLC (“EVERSANA”), ORLYNVAH™ was launched in August 2025 into the community market in the U.S. in targeted territories across seven states.Sales repre...
A director at Dorchester Minerals Lp maiden bought 4,000 shares at 25.569USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
Dorchester Minerals, L.P. Announces Acquisition of Mineral Interests DALLAS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announced today it completed an acquisition of mineral interests totaling approximately 3,050 net royalty acres located in Adams County, Colorado. The transaction was structured as a non-taxable contribution and exchange. The contributing entities conveyed their interests to the Partnership in exchange for 915,694 common units representing limited partnership interests in Dorchester Minerals, L.P. Dorchester Minerals...
Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S. FDA-approved antibiotic with the power of a penem in a novel oral formulation, offering a vital alternative in treating uncomplicated urinary tract infections DUBLIN and CHICAGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the U.S. commercial launch of ™ (sulopenem etzadroxil and...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.